L-arginine and aged garlic extract for the prevention of migraine: a study protocol for a randomised, double-blind, placebo-controlled, phase-II trial (LARGE trial)

*Devahuti R. Chaliha[1,2], Mauro Vaccarezza[1,3], Emily Corti[1], Ryusuke Takechi[1,2], Satvinder S. Dhaliwa1[1,4,5,6], Peter Drummond[7], Eric Visser[8], Fred K. Chen[9,10], Jason Charng[9,11], Virginie Lam[1,2] and John C.L. Mamo[1,2]**

[1]Curtin Health Innovation Research Institute, Faculty of Health Sciences, Curtin University, Bentley, Australia

[2]School of Population Health, Faculty of Health Sciences, Curtin University, Bentley, Australia

[3]Curtin Medical School, Faculty of Health Sciences, Curtin University, Bentley, Australia

[4]Duke-NUS Medical School, National University of Singapore, Singapore

[5]Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Pulau Pinang, Malaysia

[6]Singapore University of Social Sciences, 463 Clementi Road, Singapore 599494

[7]College of Science, Health, Engineering and Education (SHEE), Murdoch University, Murdoch, WA, Australia

[8]School of Medicine, University of Notre Dame, Fremantle, Australia

[9]Centre for Ophthalmology and Visual Science (incorporating Lions Eye Institute), The University of Western Australia, Perth, WA, Australia

[10]Ophthalmology, Department of Surgery, The University of Melbourne, East Melbourne, Victoria, Australia

[11]Department of Optometry, School of Allied Health, The University of Western Australia, Perth, WA, Australia

Correspondence:
John Curtin Distinguished Professor John Mamo
J.Mamo@Curtin.edu.au

Abstract

Introduction: Migraine is a common and distressing neurological condition characterised by recurrent throbbing headaches, nausea and heightened sensitivity to light and sound. Accumulating evidence suggests that cerebral arteries dilate during migraine, causing distal microvessels to constrict, which could activate nociceptors and cause onset of headache pain. If so, preventing or attenuating chronic microvascular constriction, and promoting a dilatory phenotype, may reduce frequency and/or severity of migraines. The primary aim of the L-Arginine and Aged Garlic Extract (LARGE) trial is to investigate whether oral treatment with dietary nutraceuticals, L-arginine and aged garlic extract (AGE), both systemic vasodilatory agents, will alleviate migraine frequency, duration and severity in adults with chronic frequent episodic migraines.

Methods and analysis: The study is a randomised double-blind placebo-controlled phase-II single-site clinical trial conducted in Perth, Australia. The target sample is to recruit 240 participants diagnosed with chronic frequent episodic migraines between 18 and 80 years of age. Participants will be randomised to one of four treatment groups for 14 weeks (placebo induction for 2 weeks, followed by 12 weeks on one of the respective treatment arms): placebo, L-arginine, AGE, or a combination of L-arginine and AGE. The doses of L-arginine and AGE are 1.5 g and 1 g daily, respectively. The primary outcome is to assess migraine response using change in migraine frequency and intensity between baseline and 12 weeks. Secondary outcomes include the impact of L-arginine and/or AGE on photosensitivity, retinal vessel changes, and blood biomarker concentrations of vascular tone, following a 12-week intervention.

Ethics and dissemination: The Curtin University Human Research Ethics Committee (HREC) has approved this study (Approval number: HRE2020-0466; Version 4; 16th August 2021). Written consent will be obtained from all participants prior to commencing their participation in the trial. The results of the study will be disseminated in peer-reviewed publications and presented at key national and international conferences and local stakeholder events.

Registration details

The trial is registered with the Australian New Zealand Clinical Trials Registry ACTRN12621001476820 (Universal Trial Number: U1111-1268-1117).

Strengths and limitations of the study

- This is the first in-human randomised double-blind placebo-controlled phase-II clinical trial examining the efficacy, safety and tolerability of L-arginine and AGE, in preventing chronic frequent episodic migraines by assessing participant-reported pain-related outcomes, and changes in photosensitivity and retinal vessels.
- The double-blinded nature of the study, and the placebo run-in for 2 weeks at the beginning of the study, are strengths in trial methodology.
- The protocol describes the oral administration of 2 nutraceutical-based interventions as possible prophylactic treatments for chronic frequent episodic migraines, with potential for direct clinical translation of outcomes.
- Potential limitations of the study include the fixed-dose design of each treatment arm and that *in vivo* neuroimaging methods, such as magnetic resonance imaging (MRI), will not be conducted to determine putative cerebro-vasodilatory changes to coincide with the outcome measures. Dose-response studies may be indicated.

Keywords

Aged garlic extract, L-arginine, chronic frequent episodic migraine, photosensitivity, randomised controlled trial, retinal imaging, vascular tone.

INTRODUCTION

Migraine is one of the most common and disabling neurovascular disorders, affecting more than one billion people worldwide (1). Considered the third most costly neurological disorder to treat, the socio-economic impacts of migraines are substantial (2, 3). The understanding of the pathophysiology and aetiology of migraines has increased substantially over the past few decades, with emergence of new therapeutic approaches. However, appropriate access and use of current therapeutic options are scant, as migraine treatments are often related to adverse effects, and are unavailable to the vast majority of patients due to strict prescribing guidelines (4-6).

The prevailing dogma of migraine suggests that vasodilatation of large cerebral arteries contributes to pain associated with migraines. We provide an alternate hypothesis for the pathophysiology of vascular-based migraines, whereby stress-induced heightened sympathetic tone results in a chronically constrictive cerebral microvascular phenotype (7). Reduced central parenchymal blood flow could then activate nociceptors and cause headache onset. Thus, we put forward the hypothesis that prevention or attenuation of chronic microvascular constriction reduces the frequency or severity of vascular-mediated headaches. There are numerous limitations with current migraine medications, including medication overuse that can paradoxically induce headache (8, 9), many are vasoconstrictive which is a contraindication for patients with cardiovascular complications (10-12), invasive subcutaneous administration, high costs, and regulatory restrictions (11, 13). Accordingly, benign vasodilating alternatives to prevent and treat patients with vascular-induced headaches need to be urgently considered.

L-arginine (2-amino-5-guanidinopentanoic acid, arginine) and aged garlic extract (AGE) are two oral nutraceutical agents that have been used to improve several cardiovascular disease risk factors via vasodilatory mechanisms (14-21). However, neither have been investigated as a prophylactic option to treat chronic frequent episodic migraines. Briefly, through enhanced biosynthesis of endothelial nitric oxide (L-arginine) or increasing systemic vasodilatory prostaglandins (AGE) amongst other anti-inflammatory and antioxidant properties, L-arginine and AGE are likely to be efficacious in attenuating migraine severity/frequency induced by cerebral microvascular constriction. A significant advantage of these two nutraceuticals over current conventional migraine drug treatments is that the safety profile of both agents has been widely documented and well-tolerated in the context of cardiovascular indications with minimal side effects.

Here, we detail the study protocol for the 'L-Arginine and Aged Garlic Extract (LARGE) for the Prevention of Migraine' trial. The study is a 12-week, phase-II, single-site, randomised, double-blind,

parallel-group-design, placebo-controlled trial, investigating the efficacy of either oral L-arginine, AGE or a combination of these nutraceuticals in adults with chronic frequent episodic migraines. Key outcome measures include frequency of migraines attacks and intensity of headache pain. Additional exploratory outcome measures include changes in photosensitivity, retinal vascular diameter, and blood biomarkers of vascular tone.

OBJECTIVES

The primary objective of this study is to evaluate the impact of oral 1.5 g/day L-arginine, 1 g/day AGE, or a combination of the two nutraceutical doses, on reducing migraine frequency and severity, compared with placebo, in adults with chronic frequent episodic migraines, over a 12-week intervention period. The secondary objectives are to measure the independent and combined effects of each intervention on physiological vasodilation in the retinal vessels, onset of photosensitivity, blood biochemical markers of vascular tone, and to evaluate the impact on quality of life, in adults with frequent episodic migraines.

METHODS AND ANALYSIS

The methods reporting of this study follow the recommendations of the Standard Protocol Items: Recommendations for Interventional Trials Statement (22).

Trial design

This is a single-site, randomised, double-blind, parallel-group-design, placebo-controlled, phase-II clinical trial on the efficacy, safety and tolerability of oral L-arginine and/or AGE in 18-80-year-old individuals with chronic frequent episodic migraines, based in Perth, Western Australia (WA). Study participants and members of the research team will be blinded to randomisation of the intervention treatments.

The maximum study duration is 14 weeks with a 2-week placebo run-in followed by a treatment period of 12 weeks. Eligible participants will be randomised to one of four parallel treatment groups in a 1:1:1:1 ratio, using permuted block randomisation: placebo, L-arginine, AGE, and combined L-arginine and AGE. Factoring for up to 20% drop-out rate, we aim to recruit 240 participants with up to 60 individuals randomised to each of the four treatment groups. **Figure 1** shows an overview of the study design for the LARGE trial. The trial is registered through the Australian New Zealand Clinical Trials Registry (ACTRN12621001476820).

Study setting and recruitment

The single-site trial will be based in Perth (WA). Study visits will be completed at the Sarich Neuroscience Research Institute (SNRI), Nedlands (WA), with retinal imaging conducted at the Lions Eye Institute (LEI), Nedlands (WA) (adjacent to SNRI). To reach the targeted sample size, potential participants will be recruited through advertising and editorials on social media, print, radio and/or television; correspondence and promotions via not-for-profit organisations and research partners; and website content.

Prospective participants will be informed that participation is voluntary, and that withdrawal of consent is possible at any time without having to provide justification. All relevant information will be disclosed during the consent procedure with the opportunity to clarify questions with the investigator team. Enrolment is only possible after written informed consent is obtained (see **Appendix 1** for participant Information Sheet and Consent Form).

Eligibility criteria

The eligibility criteria for the participants in this study are listed in **Table 1** below. The inclusion criteria must be fulfilled, and the exclusion criteria must not apply. Eligibility will be verified by delegated research personnel at the inclusion/consent visit.



Figure 1. *Overview of flow of participants. L-arg = L-arginine; AGE = aged garlic extract; OCTA = optical coherence tomography angiography. Participant self-report long-term questionnaires consist of the Migraine-Specific Quality-of-life Questionnaire (MSQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Leiden Visual Sensitivity Scale (L-VISS), and Visual Light Sensitivity Questionnaire – 8 (VLSQ-8). Migraine diaries are completed daily and weekly over the 2 and 12 weeks between visits.*

Table 1. LARGE trial inclusion and exclusion criteria.

Inclusion criteria	Exclusion criteria
1. Migraine (with or without aura) diagnosed at least 1 year ago 2. Migraine onset occurred before 50 years of age 3. Adult males and females, aged 18-80 years (inclusive) at screening 4. 2-6 migraine episodes and fewer than 6 'other' headache types per month, averaged over the previous 3 months 5. Able to differentiate between migraine and 'other' headache types 6. Able to commit to taking oral capsules once a day for 14 weeks 7. Able to fill out paper daily migraine diary over 14 weeks	1. Taking medications/drugs that affect vascular tone or blood pressure 2. Chronic daily headaches (headaches on 15/+ days/month) 3. Headache disorder or facial pain disorder other than migraine 4. Change in migraine treatment in previous 3 months 5. Taking >2 migraine-prevention drugs 6. L-arginine tablets or aged garlic extracts in previous 3 months 7. Possibility of pregnancy or breastfeeding during study 8. Adverse reactions to food containing L-arginine or garlic 9. Clinical reports of kidney/liver dysfunction 10. Known risks of bleeding or coagulopathy, or currently on blood-thinning medications 11. Cancer, haemochromatosis or diabetes 12. Severe psychiatric disorder or other neurological disorders 13. Acute/chronic pain disorders, infections, cardiovascular or cerebrovascular disease 14. Poorly controlled depression or anxiety 15. Antipsychotic or antidepressant medications/drugs over past 3 months 16. Low blood pressure or complications arising from it 17. Diagnoses other than migraine as primary cause of headaches 18. Changes in digestive system over past few months 19. Headaches cause fainting or other medical emergencies 20. Substance abuse/dependence/addiction in previous 3 months 21. Procedure or injection to treat migraine over past 3 months 22. Implanted or external nerve stimulator to treat migraines 23. Pain medications on most days a week for headaches 24. Opioid medications each day for chronic pain 25. History of overusing medications

	26. History of eye pathology, surface disorder, surgery (except cataract extraction), or injury 27. Difficulty seeing clearly (with glasses or contact lenses, if required) 28. History of diabetes, hypertension, collagen vascular disease, vasculitis, or renal disease/failure 29. Smoke >1 pack of cigarettes a day 30. Disorders of the optic nerve or retina 31. Reasons that retinae may not be clearly viewed 32. Poor image perception due to cataract or unstable fixation 33. Anaemia or iron deficiency 34. Participation in concurrent research trial

Study intervention

Intervention description and adherence

This study consists of 2 phases, including: a) a 2-week placebo run-in phase (week -2 to 0); b) a 12-week treatment phase (day 0 to day 84). Once individuals are deemed eligible according the inclusion and exclusion criteria listed in **Table 1**, participants will be asked to provide written consent and will be enrolled into the trial. At the consent visit (**visit 1**), participants will be asked to provide basic demographic information, complete medical and migraine history (i.e., duration of migraine, age of onset, monthly migraine frequency), current medication, menstrual status if applicable, and medical history. Baseline demographic and anthropometric measures were adapted from the National Institute of Neurological Disorders and Stroke Common Data Elements (www.commondataelements.ninds.nih.gov) and the PhenX toolkit (https://www.phenxtoolkit.org/), respectively. During this visit, participants will be instructed on how to fill out the daily and weekly migraine diaries. All participants are required to undergo a 2-week placebo run-in, and are required to take oral placebo capsules for 2 weeks (5 capsules per day). Thereafter, at **visit 2** (baseline), a 12-week supply of the respective randomised treatment will be dispensed to each participant; 5 capsules a day for 12 weeks (placebo; L-arginine; AGE; combination of L-arginine and AGE). Participants are contacted one week following commencement of treatment, to discuss any potential adverse events and treatment compliance.

Each participant will be provided with a paper-based diary to improve adherence of all groups (see **Appendices 2 and 3**). Treatment efficacy in terms of headache pain, severity and frequency will be evaluated by a standardised daily migraine diary (**Appendix 2**) and a weekly summarising weekly

migraine diary to track clearer long-term progress (**Appendix 3**). A capsule information sheet is dispensed with the intervention capsules to provide details instructions on missed doses where relevant. Similar to the placebo run-in, participants will be required to return capsule bottles at the end of the 12-week intervention to determine adherence to treatment. Poorly compliant participants will be excluded from subsequent analyses.

Visit 3 will be an exact replica of visit 2, with the difference that no further capsules/diaries will be given, and the visit-1 long-term questionnaires will have been filled out again to compare with the results of the visit-1 ones. Blood biomarkers, photosensitivity tests and retinal scans will be compared between visits 2 and 3 to test differences due to treatment over the 12 weeks.

Supply of intervention

Trial interventions (including placebo) are provided as identical capsules bottled in participant-ID-labelled containers by a GMP-certified compounding pharmacy, Oxford Compounding (North Perth, Australia). The placebo capsules are comprised of microcrystalline cellulose with no active ingredients. No dose modification of the trial intervention is permitted. All capsules are lightly scented with garlic to avoid potential bias.

Discontinuing or modifying allocated interventions

If a participant decides to withdraw from the project, participants are asked to notify a member of the research team. If a participant withdraws consent during the research project, relevant project team members will not collect additional personal information from the participant. However, personal information already collected will be retained to ensure that the results of the research project can be assessed and to comply with the law. Participants will be made aware that data collected by the investigator team up to the time the participant withdraws will form part of the research project results.

Relevant concomitant care during the trial

Apart from the medications in the exclusion criteria above, participants will be able to continue their regular medically prescribed regimen. Participants will be encouraged to inform their general practitioners (GPs) that they are participating in this study. Participants should not partake in other clinical trials while participating in this study.

Study procedures

Table 2, schedule of assessments, details the overall schedule of the trial.

Primary and secondary outcomes

Primary outcomes

The primary objective of the LARGE trial is to evaluate the effectiveness of oral supplementation of L-arginine, AGE or the combined treatment of oral L-arginine and AGE, in reducing the severity and frequency of migraine attacks in chronic frequent episodic migraines in adults. In accordance with the International Headache Society guidelines for RCTs in preventative treatment of episodic migraines in adults (23), the differences in the mean number of migraine episodes per month, between baseline (**visit 2**) and end of study (EoS; 12 weeks treatment, **visit 3**), will be determined as the primary outcome measure assessed by a standardised daily migraine diary (**Appendix 3**). From the daily migraine diaries, treatment efficacy will be evaluated by the mean change in outcome measures between baseline and EoS within each group, and thereafter compared with changes between each intervention group. Primary outcomes collated from the diaries include: a) mean number of migraine episodes per month (migraine frequency); b) mean number of migraine days per month; c) mean number of moderate-or-severe migraine days per month; d) mean total duration of migraines per month (hours); e) mean duration of each migraine episode (hours) per month; f) mean number of acute migraine medication doses per month; and g) number and type of self-reported adverse events per month.

Secondary outcomes

Secondary outcomes will comprise the changes in acute photosensitivity, quality of life (QoL), retinal vessel changes, and blood biomarkers of vascular tone, from baseline to EoS.

To explore the effects of each intervention arm relative to placebo on photosensitivity, a visual discomfort threshold will be determined via an acute light challenge on the second and third visits. Briefly, adapted from Woodhouse and Drummond (1993) (24), to determine the visual discomfort threshold, participants were subjected to an increased brightness of an LED panel facing them 200 cm away by 1% every 4 seconds. The percentage brightness of the Nanlite Mixpanel 150 RGBWW 150W LED Panel (emission range: 0-11,320 Lux) at which the participant expresses discomfort and requests no further increase in brightness will be recorded at both study visits and compared to determine differences if any, in visual sensitivity.

The self-reported Migraine-Specific Quality-of-life Questionnaire (version 2.1) (MSQ) (25, 26) and Short-Form McGill Pain Questionnaire (SF-MPQ) (27) will be completed by each participant at baseline and EoS. The MSQ is utilised to assess the change, before and after treatment, in each of the treatment groups in participants' day-to-day functioning in regard to impeding activity, preventing activity, and emotional feelings, that are usually affected by migraines. The SF-MPQ is used to evaluate weekly differences in pain intensity reported by each of the participants.

A number of recent studies have implicated lower vessel densities in the macula and optic nerve, as well as reduced thicknesses of the choroid and retina, in adults with migraines compared to controls without migraines (28-40). Thus, an additional exploratory outcome will comprise the changes in retinal vessel density and the foveal avascular zone area measured via optical coherence tomography angiography (OCTA), with the AngioVue Imaging System (RTVue XR Avanti, Optovue Inc., Fremont, CA, USA), at baseline and 12-weeks post intervention, as a surrogate measure of cerebral vascular changes.

Moreover, blood biomarkers of vascular tone will be analysed in samples collected at baseline and EoS. Systemic concentrations of asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA), nitrates and nitrites, and endothelin-1, will be analysed in fasted plasma samples. Among our proposed panel of biomarkers, the antagonism between vasodilatory NO and vasoconstrictive endothelin-1 allows the assessment of potential changes in vascular tone (41). Nitrates and nitrites are more stable derivatives of reactive NO in the bloodstream (42), and thus were chosen as a proxy measure of dilation of the vessels supplying the brain. ADMA and SDMA, additionally, would be valuable measures of interictal propensity to migraine, as higher levels of both vasoconstrictive molecules would reflect inhibition of vasodilatory NO production from L-arginine (41).

	STUDY PERIOD					
Visit	**Screening /enrolment**	**Visit 1 (informed consent)**		**Visit 2**		**Visit 3 (EoS)**
TIMEPOINT	***-t_1 (1 day)***	***0 (1 day)***	***t_1 (2 weeks)***	***t_2 (1 day)***	***t_3 (12 weeks)***	***t_4 (1 day)***
ENROLMENT:						
Eligibility screen	X					
Informed consent		X				
Participant demographics		X				
Participant anthropometric measures		X				
Group allocation		X				
INTERVENTIONS:						
Placebo			X		X	
L-arg					X	
AGE					X	
L-arg + AGE					X	
ASSESSMENTS:						

Daily and weekly migraine diaries			X		X	
MSQ		X				X
SF-MPQ		X				X
L-VISS		X				X
VLSQ-8		X				X
OCTA				X		X
Acute light challenge				X		X
Blood markers				X		X

Table 2. *Schedule of assessments. L-arg = l-arginine; AGE = aged garlic extract; t = timepoint; MSQ = Migraine-Specific Quality-of-life Questionnaire; SF-MPQ = Short-Form McGill Pain Questionnaire; L-VISS = Leiden Visual Sensitivity Scale; VLSQ-8 = Visual Light Sensitivity Questionnaire – 8; OCTA = optical coherence tomography angiography.*

Statistical analysis

Sample size and statistical power

We propose an RCT with a factorial treatment structure. This design is efficient and allows the estimation of both the main effects of L-arginine and AGE, and the interaction between L-arginine and AGE. This design with two factors at 2 and 2 levels has 4 arms/groups (treatment combinations). A total of 240 individuals are required to provide 60 subjects per group. This design achieves 87% power when an F-test is used to test factor L-arginine at a 5% significance level with the effect size of 0.2; achieves 87% power when an F-test is used to test factor AGE at a 5% significance level with the effect size of 0.2; and achieves 87% power when an F-test is used to test the L-arginine*AGE interaction at a 5% significance level with the effect size of 0.2. Cohen's Effect Size Table (43) provides the interpretation of effect sizes as: Small: 0.1; Medium: 0.25; Large: 0.40. Our research study can therefore detect between small and medium effect sizes between each of the main effects and interactions. An estimated effect size of 0.2, used in the sample size calculation for testing the main effects and interaction, was obtained from our preliminary data. Assuming a dropout rate of 20%, a total of 300 participants will be initially recruited into the study, with 75 participants in each of the 4 treatment combinations.

Statistical methods

We will analyse the data using IBM SPSS® Statistics for Windows, Version 24.0 (IBM Corp., Armonk NY, USA and Stata Version 17 (StataCorp, 4905 Lakeway Dr., College Station, TX 77845, USA)). P-values less than 0.05 will be considered statistically significant. Continuous data will be reported as a group mean ± standard deviation (SD), and categorical data as count (percentage). Data from continuous variable outcomes will be analysed using an Analyse of Covariance procedure as a General Linear Model, with the baseline values as covariates. Post-hoc comparison of means between the 4 treatment combinations will only be conducted if the interaction between sex and treatment is statistically significant. We will take differences between treatment groups as mean differences with associated 95% confidence intervals. We will analyse categorical outcome variables using a Multivariable Logistic Regression Model, with the baseline values as covariates. Treatment effects will be expressed as odds ratios with associated 95% confidence intervals. Residuals from each of the analyses will be inspected to ensure validity of the statistical procedures utilised. Appropriate graphical displays will be used to demonstrate and communicate the main effects and interactive effects of the treatment groups.

Allocation

We are using block randomisation: eligible subjects will be computer-randomised in blocks of 8, to one of the 4

treatment groups (placebo control, L-arginine, aged garlic extract (AGE), and L-arginine + AGE). Each participant will be randomised by participant ID, as this should preclude group allocation by order of study entry, as per the IHS guidelines (44, 45). We will do this as the participants enter the trial, whereby the statistician will then have access to the list on the Research Data Capture (REDCap) tool where we will be entering all participant details and responses.

Implementation

The randomisation schedule is sent to an independent pharmacist (Oxford Pharmaceuticals) who will then dispense trial intervention in blank packaging with only the participant ID displayed. The investigators will receive this by post, and will supply each participant with the treatment pack on visits 1 and 2 (placebo for 2 weeks, then randomised treatment for 12 weeks).

Blinding

Although participants will be blinded to treatment allocation, we will inform them of the general nature and composition of the treatment prior to their participating. The investigator team will be blinded as to which treatment we are giving which participant, during the 12 intervention weeks. Only the statistician and pharmacist will not be blinded as to which participant receives which treatment, as they will be handling the randomisation schedules linking identification numbers to participant names. In case of emergency (an adverse event sustained by the participant, which requires medical treatment to know which study treatment has been given), the investigator will break the seal and be unblinded as to which treatment the participant has received. This will immediately be reported back to the investigator team and the HREC.

Data collection and management

Data will be collected by delegated personnel from the research team. We will compile de-identified data into monthly data sets, using Microsoft Excel® Version 15.0 (Microsoft Corporation, Redmond WA, USA). For OCTA, photosensitivity and plasma biomarkers, the computed results will be copied via a password-protected USB stick to the university research drive. Identifiable data will be sorted by date in separate folders according to each questionnaire, and stored in a locked filing cabinet with access restricted to the investigator team. All other data will be de-identified to ensure confidentiality of participant data. Data will be stored on a password-protected web-enabled clinical-trial-data electronic management system (REDCap) located in an ISO27001-compliant facility at Curtin University. Participants' study information will not be released outside of the study

without the written permission of the participant. All data will be securely archived as per the Institute's data policy for a minimum of 15 years.

Patient and public involvement

No participants were involved in the design of this study

Research ethics approval and dissemination

The LARGE trial has been approved by the Curtin University Human Research Ethics Committee (HREC) (Approval number: HRE2020-0466; Version 4; 16th August 2021). The trial is registered with the WHO Trial Registration Data Set. The Universal Trial Number is U1111-1268-1117. Written consent will be obtained from all participants prior to commencing their participation in the trial. The consent form is included as **Appendix 1**.

The results of the study will be disseminated in peer-reviewed publications and presented at key national and international conferences and local stakeholder events.

Trial status

Participant recruitment commenced in May 2021, and is expected to complete in 2023.

Abbreviations

L-arg = L-arginine

AGE = aged garlic extract

CHIRI = Curtin Health Innovation Research Institute

GP = general practitioner

HREC = Human Research Ethics Committee

IHS = International Headache Society

LED = light-emitting diode

LEI = Lions Eye Institute

L-VISS = Leiden Visual Sensitivity Scale

MSQ = Migraine-Specific Quality-of-life Questionnaire

OCTA = optical coherence tomography angiography

PGE-5 = phosphodiesterase type 5

REDCap = Research Data Capture

SF-MPQ = Short-Form McGill Pain Questionnaire

SNRI = Sarich Neuroscience Research Institute

VLSQ-8 = Visual Light Sensitivity Questionnaire – 8

Declarations

No competing interests declared.

Acknowledgements

The authors wish to thank Dr. Fred Chen and Dr. Jason Charng for providing training for the OCTA.

Authors' contributions

DC and VL wrote the manuscript, and led the study design and protocol development. MV supervised and edited the final manuscript. EC trained and aided DC in the clinical trial coordination. PD and EV provided advice on study design and methodologies. VL and RT provided advice on study design, recruitment, data acquisition and editing of the manuscript. SD was the lead statistician and advised on study design and power calculations. JM conceived the study concept, study design, and edited the final manuscript. All authors have read and approved the final manuscript.

Funding

This work was supported by Multiple Sclerosis, Western Australia (MSWA).

Disclaimer

MSWA do not have any responsibility relating to study design, collection, management, analysis of data, writing of report, or submission of report for publication.

Availability of data and materials

All investigators will have access to the final dataset.

Competing interests

The authors declare that they have no competing interests.

References

1. Ashina M, Katsarava Z, Do TP, Buse DC, Pozo-Rosich P, Özge A, et al. Migraine: epidemiology and systems of care. Lancet. 2021.
2. Andlin-Sobocki P, Jönsson B, Wittchen H-U, Olesen J. Cost of disorders of the brain in Europe. European Journal of Neurology. 2005;12(s1):1-27.
3. Leonardi M, Steiner TJ, Scher AT, Lipton RB. The global burden of migraine: measuring disability in headache disorders with WHO's Classification of Functioning, Disability and Health (ICF). The journal of headache and pain. 2005;6(6):429.
4. Gallagher RM, Kunkel R. Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment. Headache: The Journal of Head and Face Pain. 2003;43(1):36-43.
5. Negro A, Martelletti P. Patient selection for migraine preventive treatment with anti-CGRP (r) monoclonal antibodies. Expert Review of Neurotherapeutics. 2019;19(8):769-76.
6. Sussman M, Benner J, Neumann P, Menzin J. Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: results from the US societal and payer perspectives. Cephalalgia. 2018;38(10):1644-57.
7. Chaliha DR, Vaccarezza M, Takechi R, Lam V, Visser E, Drummond P, et al. A Paradoxical Vasodilatory Nutraceutical Intervention for Prevention and Attenuation of Migraine-A Hypothetical Review. Nutrients. 2020;12(8).
8. Thorlund K, Sun-Edelstein C, Druyts E, Kanters S, Ebrahim S, Bhambri R, et al. Risk of medication overuse headache across classes of treatments for acute migraine. The journal of headache and pain. 2016;17(1):107.
9. Bigal ME, Lipton RB. Overuse of acute migraine medications and migraine chronification. Current pain and headache reports. 2009;13(4):301-7.
10. Adelman JU, Adelman RD. Current options for the prevention and treatment of migraine. Clinical therapeutics. 2001;23(6):772-88.
11. Ashina M, Buse DC, Ashina H, Pozo-Rosich P, Peres MF, Lee MJ, et al. Migraine: integrated approaches to clinical management and emerging treatments. The Lancet. 2021.
12. MaassenVanDenBrink A, Meijer J, Villalón CM, Ferrari MD. Wiping out CGRP: potential cardiovascular risks. Trends in pharmacological sciences. 2016;37(9):779-88.
13. Charles A, Pozo-Rosich P. Targeting calcitonin gene-related peptide: a new era in migraine therapy. The Lancet. 2019;394(10210):1765-74.
14. Creager MA, Gallagher SJ, Girerd XJ, Coleman SM, Dzau VJ, Cooke JP. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. The Journal of clinical investigation. 1992;90(4):1248-53.
15. Bode‐Böger SM, Böger RH, Galland A, Tsikas D, Frölich JC. L‐arginine‐induced vasodilation in healthy humans: pharmacokinetic−pharmacodynamic relationship. British journal of clinical pharmacology. 1998;46(5):489-97.
16. Bode-Böger SM, Böger RH, Alfke H, Heinzel D, Tsikas D, Creutzig A, et al. L-Arginine induces nitric oxide–dependent vasodilation in patients with critical limb ischemia: a randomized, controlled study. Circulation. 1996;93(1):85-90.
17. Morikawa E, Moskowitz MA, Huang Z, Yoshida T, Irikura K, Dalkara T. L-arginine infusion promotes nitric oxide-dependent vasodilation, increases regional cerebral blood flow, and reduces infarction volume in the rat. Stroke. 1994;25(2):429-35.
18. Girerd XJ, Hirsch AT, Cooke JP, Dzau VJ, Creager M. L-arginine augments endothelium-dependent vasodilation in cholesterol-fed rabbits. Circulation research. 1990;67(6):1301-8.

19. Williams MJ, Sutherland WH, McCormick MP, Yeoman DJ, de Jong SA. Aged garlic extract improves endothelial function in men with coronary artery disease. Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives. 2005;19(4):314-9.
20. Weiss N, Ide N, Abahji T, Nill L, Keller C, Hoffmann U. Aged garlic extract improves homocysteine-induced endothelial dysfunction in macro-and microcirculation. The Journal of nutrition. 2006;136(3):750S-4S.
21. Wlosinska M, Nilsson AC, Hlebowicz J, Malmsjö M, Fakhro M, Lindstedt S. Aged garlic extract preserves cutaneous microcirculation in patients with increased risk for cardiovascular diseases: a double‐blinded placebo‐controlled study. International wound journal. 2019;16(6):1487-93.
22. Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. Bmj. 2013;346.
23. Diener H-C, Tassorelli C, Dodick DW, Silberstein SD, Lipton RB, Ashina M, et al. Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. Cephalalgia. 2020;40(10):1026-44.
24. Woodhouse A, Drummond PD. Mechanisms of Increased Sensitivity to Noise and Light in Migraine Headache. Cephalalgia. 1993;13(6):417-21.
25. Cole JC, Lin P, Rupnow MFT. Validation of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ v. 2.1) for patients undergoing prophylactic migraine treatment. Quality of Life Research. 2007;16(7):1231-7.
26. Martin BC, Pathak DS, Sharfman MI, Adelman JU, Taylor F, Kwong WJ, et al. Validity and reliability of the migraine‐specific quality of life questionnaire (MSQ Version 2.1). Headache: The Journal of Head and Face Pain. 2000;40(3):204-16.
27. Melzack R. The short-form McGill pain questionnaire. Pain. 1987;30(2):191-7.
28. Chang MY, Phasukkijwatana N, Garrity S, Pineles SL, Rahimi M, Sarraf D, et al. Foveal and peripapillary vascular decrement in migraine with aura demonstrated by optical coherence tomography angiography. Investigative ophthalmology & visual science. 2017;58(12):5477-84.
29. Ulusoy MO, Horasanlı B, Kal A. Retinal vascular density evaluation of migraine patients with and without aura and association with white matter hyperintensities. Acta Neurologica Belgica. 2019;119(3):411-7.
30. Karalezli A, Celik G, Koktekir BE, Kucukerdonmez C. Evaluation of choroidal thickness using spectral-domain optical coherence tomography in patients with migraine: a comparative study. European journal of ophthalmology. 2015;25(4):348-52.
31. Ascaso FJ, Marco S, Mateo J, Martínez M, Esteban O, Grzybowski A. Optical coherence tomography in patients with chronic migraine: literature review and update. Frontiers in neurology. 2017;8:684.
32. Taşlı NG, Ersoy A. Altered Macular Vasculature in Migraine Patients without Aura: Is It Associated with Ocular Vasculature and White Matter Hyperintensities? Journal of Ophthalmology. 2020;2020.
33. Dadaci Z, Doganay F, Acir NO, Aydin HD, Borazan M. Enhanced depth imaging optical coherence tomography of the choroid in migraine patients: implications for the association of migraine and glaucoma. British Journal of Ophthalmology. 2014;98(7):972-5.
34. Unlu M, Sevim DG, Gultekin M, Baydemir R, Karaca C, Oner A. Changes in retinal vessel diameters in migraine patients during attack-free period. International journal of ophthalmology. 2017;10(3):439.
35. Karaca EE, Koçer EB, Özdek Ş, Akçam HT, Ercan MB. Choroidal thickness measurements in migraine patients during attack-free period. Neurological Sciences. 2016;37(1):81-8.
36. Reggio E, Chisari CG, Ferrigno G, Patti F, Donzuso G, Sciacca G, et al. Migraine causes retinal and choroidal structural changes: evaluation with ocular coherence tomography. Journal of neurology. 2017;264(3):494-502.
37. Demircan S, Ataş M, Arık Yüksel S, Ulusoy MD, Yuvacı İ, Arifoğlu HB, et al. The impact of migraine on posterior ocular structures. Journal of ophthalmology. 2015;2015.

38. Gunes A, Demirci S, Tok L, Tok O, Demirci S, Kutluhan S. Is retinal nerve fiber layer thickness change related to headache lateralization in migraine? Korean Journal of Ophthalmology. 2016;30(2):134-9.
39. Simsek IB. Retinal nerve fibre layer thickness of migraine patients with or without white matter lesions. Neuro-Ophthalmology. 2017;41(1):7-11.
40. Martinez A, Proupim N, Sanchez M. Retinal nerve fibre layer thickness measurements using optical coherence tomography in migraine patients. British Journal of Ophthalmology. 2008;92(8):1069-75.
41. Paolucci M, Altamura C, Vernieri F. The Role of Endothelial Dysfunction in the Pathophysiology and Cerebrovascular Effects of Migraine: A Narrative Review. Journal of Clinical Neurology. 2021;17(2):164-75.
42. Piknova B, Park JW, Cassel KS, Gilliard CN, Schechter AN. Measuring Nitrite and Nitrate, Metabolites in the Nitric Oxide Pathway, in Biological Materials using the Chemiluminescence Method. J Vis Exp. 2016(118):54879.
43. Cohen J. The Analysis of Variance. Statistical Power Analysis for the Behavioural Sciences Hillsdale, New Jersey: Lawrence Erlbaum Associates 1988. p. 285-7.
44. Tfelt-Hansen P, Pascual J, Ramadan N, Dahlof C, D'Amico D, Diener H-C, et al. Guidelines for controlled trials of drugs in migraine: Third edition. A guide for investigators. Cephalalgia. 2012;32(1):6-38.
45. Tassorelli C, Diener H-C, Dodick DW, Silberstein SD, Lipton RB, Ashina M, et al. Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia. 2018;38(5):815-32.

Appendices

Appendix 1

1. Information Sheet

Migraine Treatment Research Project
Participant Information Sheet

You have been asked to participate in this study involving a new treatment for migraines. Please read this document carefully and ask any questions you wish. Knowing what is involved will help you decide if you want to take part in this research. Before deciding whether to take part, you might want to talk about it with a relative, friend or your local doctor. Participation in this research is voluntary. Do not sign this informed consent form unless you fully understand the nature of the study and any possible side effects. There will be ample opportunity for you to meet the investigators and have the study procedures and protocol fully explained to you.

Background information

Migraine is a very common and distressing neurological condition that causes symptoms such as recurrent throbbing headaches, nausea and disturbed vision. Migraines are caused by the interaction between the brain and blood vessels of the brain. Migraines are conventionally believed to occur because of the dilation (opening) of the large vessels in the brain, which leads to activation of pain receptors in the brain which causes the common symptoms of migraines. The medications currently offered do not seem to address the main cause of migraines, and have many adverse effects.

Recent research findings suggest that migraines may occur due to the constriction (tightening) of the smaller vessels of the brain, that leads to oxygen and nutrient insufficiency, causing vascular headaches; however, there are questions that still need to be answered. There are certain dietary compounds that can increase the dilation of smaller blood vessels, and our research project will investigate if these compounds can reduce the frequency and severity of migraine symptoms. These include L-arginine and aged garlic extract. L-arginine is an amino acid commonly found in food, that helps the body build protein. It is found in meat, dairy, eggs and seeds. Aged garlic extract is derived from garlic which is a common ingredient in food. Garlic is actually known to have beneficial antioxidant, anti-thrombotic and anti-atherosclerotic properties. Neither have been commonly known to cause adverse effects when included in the human diet.

In this study, researchers are seeking participants to investigate the preventive/treatment effects of L-arginine and aged garlic extract in reducing migraines headaches both in the short- and the long-term. This study is a double-blind study. To ensure we test without bias whether each intervention is effective in reducing the severity of migraines, participants will be randomly assigned to one of four groups: group 1 (placebo); group 2 (L-arginine); group 3 (aged garlic extract); or group 4 (a combination of L-arginine and aged garlic extract). You will be randomly allocated (by computer) and have an equal chance to be in any of the groups. As this is a double-blind study, neither you nor the research team will know which group you are allocated to, in order to reduce bias throughout the treatment.

Inclusion/exclusion criteria

To be eligible for this trial, you must fulfil the following inclusion criteria:

1. Migraine (with or without aura) diagnosed at least 1 year ago
2. Migraine onset occurred before 50 years of age
3. 2-6 migraine episodes and fewer than 6 'other' headache types per month, over the last 3 months
4. Able to distinguish between migraine and 'other' headache types
5. Able to complete a daily diary about migraine experience

6. Able to commit to taking the 5 capsules a day for 14 weeks

If you meet any of the following criteria, you <u>will not be eligible</u> for the study:

1. Taking medications/drugs affecting vascular tone or blood pressure
2. Taking nitrate drugs or isoproterenol (often prescribed for angina or heart failure)
3. Taking more than two migraine-prevention drugs
4. Taking antidepressants or diuretics, herbs, supplements
5. Taking Sildafenil, Cialis, Spedra and any other PGE-5 inhibitor drugs
6. Taking drugs with potential blood-vessel effects (analgesics, decongestants, or antihistamines)
7. Already taking L-arginine or garlic supplements for 3 months before the study
8. Having headaches causing fainting or another medical emergency
9. Having chronic daily headaches, medication-overuse headaches and/or other secondary headache disorders
10. Having diagnoses other than migraine as the primary cause of headache
11. A change in migraine treatment in the 3 months prior to or during the study
12. Clinical reports of renal or liver dysfunction
13. Clinical risks associated with bleeding or coagulopathy or currently on blood-thinning medications such as warfarin/heparin therapy
14. Having any cardiovascular or neoplastic diseases
15. Having major chronic metabolic or neurologic disorders, or receiving current therapy for them
16. Being diagnosed with psychosis or bipolar affective disorder
17. Diagnosis of cancer
18. Substance abuse/dependence/addiction in the 3 months prior to or during the study
19. Having a history of diabetes, hypertension, collagen vascular disease, vasculitis, or renal disease/failure
20. Having any low-blood-pressure-related issues or Type-1 or -2 diabetes
21. Having the possibility of pregnancy or lactation
22. Being allergic to garlic or its constituents
23. Having gastric disturbances such as bloating, stomach pain, heartburn, diarrhoea, constipation, nausea or vomiting
24. Are a smoker of >1 pack a day
25. Having a history of eye pathology, surface disorder, surgery (except cataract extraction), injury
26. Not being able to see clearly (with glasses/contacts, if need be)
27. Having disorders of the optic nerve (including glaucoma) or retina
28. The significant possibility of our not being able to see the inside of your eye clearly
29. Having poor image perception due to cataract or unstable fixation

What does the study involve?

This study is open to adults aged between 18 and 80, who currently experience migraines. This is a randomised controlled trial, which means that study participants will be randomly placed into groups and given different treatments in order for the results from each to be compared. You will be randomly allocated to one of 4 study groups. Your participation in this study involves a considerable time commitment with a total of **3 visits** over a period of 14 weeks. The 3 visits will take approximately 30 to 60 minutes each.

<u>Before your appointment:</u>

Prior to your first visit, you will be sent a few questionnaires that need to be completed and brought with you to your first visit. These questionnaires will ask about your experience with migraines and the impact of migraines on your daily life. If you have not completed the questionnaires prior to your first visit, there will be time to complete the questionnaires during the visit.

Visit 1:
You will be asked to attend an appointment at the Sarich Institute (8 Verdun St, Nedlands WA 6009). During this appointment, we will discuss the study requirements and go over the inclusion and exclusion criteria for the study. If you are eligible for the study, we will measure your body weight, height, waist and hip circumferences, blood pressure and heart rate. Next, we will provide you with a treatment pack of capsules to take every day for 2 weeks. During the next 2 weeks, we ask you to take ***five (5)*** capsules each day, and complete a hardcopy daily and weekly migraine diary we will provide you with. This session should take approximately 30 minutes.

Visit 2:
2 weeks after Visit 1, you will be asked to attend the Sarich Institute again (8 Verdun St, Nedlands WA 6009). During this session, we will take a sample of your blood and measure your blood pressure, and you will be asked to complete a light-sensitivity task and undergo an eye (retinal) scan. For the blood collection, we will ask you to come in fasted (8-12 hours), only consuming water before we collect your blood. All blood samples will be collected by a certified phlebotomist. If we cannot collect a blood sample from you, you may be requested to visit PathWest for a blood test. In the rare event of a medical emergency, fully qualified physicians and nursing staff from the Sarich Institute will be available. The retinal imaging is completely non-invasive and pain-free (it does not even require eye drops), and it should only take 5 minutes to scan each eye. The reason for this retinal scan is that the small vessels of the eye (within the retina) are considered an extension of the tiny blood vessels of the brain, and therefore may serve as a surrogate marker of central nervous system (brain) small-vessel response to our treatment.

For the light-sensitivity task, you will be asked to sit in a dark room, and we will increase the luminosity of a light panel in front of you in a step-wise fashion until you feel the light is becoming uncomfortable, or continued exposure to the light would bring on a migraine. This may cause some discomfort; however, this will be aborted as soon as you indicate the light is uncomfortable.

Finally, you will receive your second treatment pack, comprising treatment doses to last the next 12 weeks. Again, we ask you to take the capsules and complete the migraine diary on a daily basis for the next 12 weeks. This session should last approximately 60 minutes.

Visit 3:
After 12 weeks, you will be asked to visit the Sarich Institute (8 Verdun St, Nedlands WA 6009) one last time. Prior to the appointment, you will be sent questionnaires that need to be completed prior to your appointment. These are the same questionnaires that you completed prior to visit 1. If you are unable to complete the questionnaires prior to the visit, there will be time during the visit to complete the questionnaires. Visit 3 will include the same assessments as visit 2. This session should last approximately 60 minutes.

Possible adverse effects
The blood collection during each visit may cause discomfort, as we will use a needle to collect the blood. Although we will try to collect the blood from different sites, it is possible that you may find the number of blood samples collected an uncomfortable experience. Therefore, it is important to inform us if this is the case and to know that you are free to withdraw from the study at any stage. For us, your comfort during the procedure is of more concern than our ability to collect both blood samples. In some people, slight bruising and tenderness may appear afterwards at the site of venepuncture. These side effects are only minor, and will return to normal in a matter of days. The volume of blood collected should not cause you any risk of becoming anaemic (approximately 6 tablespoons). Moreover, the visits have been spaced 12 weeks between each visit, so that new red blood cells will be ready to enter the circulation. However, we advise you not to donate blood during the period of study. If you need to do any routine clinical test with blood collection, this is not a problem.

L-arginine and aged garlic extract have not been known to cause any serious adverse effects. You may experience some gastric disturbances, and in rare cases, nausea and vomiting. We will contact you after the first week of the first 2-week treatment period, and after the first week of the second 12-week treatment period, to check how you are going.

Ability to withdraw from the study

It must be stressed that your participation in this study is entirely voluntary; you are free to withdraw from the study at any stage. It is important that you do not feel any pressure to complete the study, particularly if it is not what you had originally anticipated. In the event that you withdraw or discontinue your participation in the project, we will ask your permission to use the data you have already provided. If you do not want your data to be retained, all data relating to your participation will be destroyed. In some instances, it may be required that we retain information about any adverse events you may have experienced. You will not be identifiable from this data. If you are currently enrolled as a student at Curtin University, there will be no impact on your studies if you were to withdraw from the study.

Benefits to the participant

This study may not be of direct benefit to you; however, by taking part in this study, you will gain useful information about your vascular tone as a migraineur. We encourage you to let your doctor know that you are taking part in our study. Any results that are out of clinical range will be sent to your general practitioner with your consent. Your participation in this study will provide us with important data, enabling us to investigate further the role of L-arginine and aged garlic extract in treating and/or preventing vascular headaches, especially migraines.

What happens when the research project ends?

Your data will be stored for a minimum of 15 years after the study, then destroyed. If published studies suggest benefits are realised via the indicated treatments being trialed, we will recommend participants discuss with their primary care provider, consideration for prevention and attenuation of migraine pain frequency and intensity. You will have the option of being contacted with the results of the study.

Confidentiality

Any information that you provide us will be stored securely, to protect your privacy. Some of your data may include personal information such as your name, date of birth and/or a reference number. This information will be separate to your actual data (assessment scores) and your data will be de-identified. The security of standards of all personal information follows Curtin University data-management guidelines. All information will be held in secure, locked filing cabinets at Curtin University, or on a password-protected computer database held on a secure system, which allows access to authorised individuals only. It is possible that the results from this study will also be utilised in future studies on a similar topic; however, your identity will never be disclosed. All information will be strictly confidential, and any publications arising from this work will not include your name or any other identifying feature.

Site map and parking

Here is visitor-parking information around the Sarich Institute: https://qeiimc.health.wa.gov.au/travel-access/parking/visitor-parking/. Your visits will take up to an hour, and therefore will be $3.40 on the parking meter. Below is the site map, with the relevant areas circled in red. As you can see, there are 4 available carparks near the precinct.



Should you get lost on the way, please don't hesitate to call Debs on (04) 517 176 70.

Further information

If you have queries or require urgent contact, call Debs Chaliha on 0451717670.

If you have extensive queries or require further clarification, please contact the lead investigator:

Professor John Mamo
School of Public Health, Curtin University
Phone: (08) 9266 7232
Email: J.Mamo@Curtin.edu.au

Curtin University Human Research Ethics Committee (HREC) has approved this study (HRE2020-0466). The Committee is comprised of members of the public, academics, lawyers, doctors and pastoral carers. Its main role is to protect participants. If needed, verification of approval can be obtained either by writing to the Curtin University Human Research Ethics Committee, c/- Office of Research and Development, Curtin University, GPO Box U1987, Perth, 6845, by telephoning 9266 2784, or by emailing hrec@curtin.edu.au.

HREC Project Number	*HRE2020-0466*
Project Title	*Migraine Treatment Research Project (NOPAIN)*
Principal Investigator	*Prof. John Mamo (Director of Curtin Health Innovation Research Institute)*
Student Researcher	*Devahuti (Debs) Chaliha*
Version Number	*3*
Version Date	*24 Feb 2021*

- I have read the information statement version listed above, and I understand its contents.
- I believe I understand the purpose, extent and possible risks of my involvement in this project.
- I have had an opportunity to ask questions, and I am satisfied with the answers I have received.
- I understand that I will be randomly allocated to one of four possible treatment groups, and that neither I nor the trial coordinator will know which group I am in.
- I voluntarily consent to take part in this research project, and understand that I can withdraw at any time without prejudice.
- I understand that my data will be stored for 15 years following the completion of the study, after which time it will be destroyed.
- I understand that this project has been approved by Curtin University Human Research Ethics Committee, and will be carried out in line with the National Statement on Ethical Conduct in Human Research (2007).
- I have received a copy of this Information Statement and Consent Form.

Participant Name	
Participant Signature	
Date	

Declaration by researcher: I have supplied an Information Letter and Consent Form to the participant who has signed above, and believe that they understand the purpose, extent and possible risks of their involvement in this project.

Researcher Name	
Researcher Signature	
Date	

Note: All parties signing the Consent Form must date their own signature.

Appendix 2

Daily Migraine Diary

Patient ID:	**Date**:

Did you have a migraine today? Yes ☐ No ☐

- *If **NO**, please leave the remaining of today's diary blank.*
- *If **YES**, please answer the questions below.*

Frequency: How many migraine attacks did you have today, separated by 2 hours each?

Severity: On average, how severe was (were) the migraine(s)? The following line represents increasing pain intensity from 'no pain' to 'worst possible pain'. Place a mark on the line that you feel best describes your level of pain.

No Pain — **Worst Possible Pain**

Score in mm
(Investigator's use only)

Did you take anything to help relieve the pain? Yes ☐ No ☐

If YES, please list all medications, including over-the-counter medications.

Medication name	**Number of tablets taken**

BEFORE YOUR MIGRAINE BEGAN, did you experience any of the following? Select all that apply.

☐ Changes in vision	☐ Changes in smell	☐ Changes in sound	☐ Change in taste
☐ Excessive sleepiness	☐ Trouble talking	☐ Confusion	☐ Nausea (feeling sick)
☐ Vomiting	☐ Anxiety/irritability	☐ Low mood	☐ Neck ache
☐ Unsure	☐ None listed		

BEFORE YOUR MIGRAINE BEGAN, did you have numbness or tingling in your face or arms?

Yes ☐ No ☐ Unsure ☐

BEFORE AND/OR DURING YOUR MIGRAINE, did you experience any of the following sensations? Select all that apply.

☐ Throbbing	☐ Shooting	☐ Stabbing	☐ Sharp
☐ Cramping	☐ Gnawing	☐ Hot/burning	☐ Aching
☐ Heavy (like a weight)	☐ Tender	☐ Splitting	☐ Tiring/exhausting
☐ Sickening	☐ Fear-causing	☐ Punishing/cruel	

Appendix 3

Weekly Migraine Summary

Patient ID:	**Week:**
Did you have a migraine over the past 7 days? Yes ☐ No ☐	

Short-Form McGill Pain Questionnaire

PLEASE DESCRIBE YOUR PAIN DURING THE LAST WEEK *(Check off one box per line.)*

	None	Mild	Moderate	Seve re
1. Throbbing	0 ☐	1 ☐	2 ☐	3 ☐
2. Shooting	0 ☐	1 ☐	2 ☐	3 ☐
3. Stabbing	0 ☐	1 ☐	2 ☐	3 ☐
4. Sharp	0 ☐	1 ☐	2 ☐	3 ☐
5. Cramping	0 ☐	1 ☐	2 ☐	3 ☐
6. Gnawing	0 ☐	1 ☐	2 ☐	3 ☐
7. Hot-burning	0 ☐	1 ☐	2 ☐	3 ☐
8. Aching	0 ☐	1 ☐	2 ☐	3 ☐
9. Heavy (like a weight)	0 ☐	1 ☐	2 ☐	3 ☐
10. Tender	0 ☐	1 ☐	2 ☐	3 ☐
11. Splitting	0 ☐	1 ☐	2 ☐	3 ☐
12. Tiring-Exhausting	0 ☐	1 ☐	2 ☐	3 ☐
13. Sickening	0 ☐	1 ☐	2 ☐	3 ☐
14. Fear-causing	0 ☐	1 ☐	2 ☐	3 ☐
15. Punishing-Cruel	0 ☐	1 ☐	2 ☐	3 ☐

PLEASE RATE YOUR PAIN DURING THE LAST WEEK
The following line represents pain of increasing intensity from "no pain" to "worst possible pain". Place a vertical mark (|) across the line in the position that best describes your pain **during the last week.**

No Pain — **Worst Possible Pain**

☐☐☐
Score in mm
(Investigator's use only)

CURRENT PAIN INTENSITY

0 ☐ No pain
1 ☐ Mild
2 ☐ Discomforting
3 ☐ Distressing
4 ☐ Horrible
5 ☐ Excruciating

Questionnaire developed by: Ronald Melzack